Evidence map›Paper›PMID 42870438›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2026

Ptpn1 deficiency collaborates with a NUP98::HOXD13 fusion gene to generate B cell precursor acute lymphoblastic leukemia.

Nupur Nigam, Toshihiro Matsukawa, Ryan Bertoli, Michel L Tremblay, Mianmian Yin, Yongmei Zhao, Yang Jo Chung, Peter D Aplan

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nupur NigamGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Toshihiro MatsukawaGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Ryan BertoliGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Michel L TremblayDepartment of Biochemistry, McGill University, Montreal, QC, Canada.
Mianmian YinGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.ORCID 0000-0001-5573-8991
Yongmei ZhaoSequencing Facility Bioinformatics Group, Advanced Biomedical and Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Yang Jo ChungGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Peter D AplanGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.ORCID 0000-0001-5686-9969

Funding

Activation of Proto-Oncogenes by Chromosomal TranslocationZIASC010378 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI APLAN, PETER · 2009 to 2025
$8.4M
Collaborative Pathways that Lead to LeukemiaZ01BC010982 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APLAN, PETER · 2008 to 2008
$344k
Intramural NIH HHS Z01 BC010982Intramural NIH HHS ZIA SC010378Intramural Research Program of the National Cancer InstituteNIH HHS BC 010982NIH HHS ZIA SC 010378
6 · The paper itself

Abstract

B cell precursor acute lymphoblastic leukemia (BCP ALL) is driven by a combination of genetic alterations that promote invasion and expansion of undifferentiated B cells. Mice that express a NUP98::HOXD13 (NHD13) fusion gene in hematopoietic cells develop a wide range of hematologic malignancy, and when crossed to mice that are prone to develop copy number aberrations (CNA), develop BCP ALL, accompanied by homozygous mutations of Ptpn1. To determine if Ptpn1 deletion can be a causal event leading to BCP-ALL, we crossed NHD13 mice with Ptpn1-/- mice. Mice with NHD13 expression and homozygous Ptpn1 loss developed BCP ALL with a penetrance of 70%, suggesting that Ptpn1 can function as a tumor suppressor gene in this context. Moreover, NHD13/Ptpn1+/- mice that developed BCP ALL typically showed a loss of the Ptpn1 wild type allele in leukemia cells, supporting the assertion that Ptpn1 can function as a tumor suppressor gene. Whole exome sequencing revealed acquired mutations in pathways typically mutated in human BCP ALL, such as B cell differentiation, signal transduction, and cytokine signaling. Transcriptomic analysis indicated -upregulation of signaling pathways in mitochondrial reprogramming and oxidative phosphorylation. In conclusion, we demonstrate the role of Ptpn1 as a tumor suppressor in controlling the development of B cell malignancies.

Indexed as

Homeodomain ProteinsOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProtein Tyrosine Phosphatase, Non-Receptor Type 1AnimalsHumansMiceMice, KnockoutNuclear Pore Complex ProteinsHomeodomain Proteinsnuclear pore complex protein 98Nuclear Pore Complex ProteinsOncogene Proteins, FusionProtein Tyrosine Phosphatase, Non-Receptor Type 1Ptpn1 protein, mouseB cell acute lymphoblastic leukemiaB cell developmentmouse modelNUP98 fusionPtpn1

Identifiers

PMID42870438
PMCPMC13661600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.